People with more severe cases of psoriasis may be at increased risk of uncontrolled hypertension, according to a study published online Oct. 15 in JAMA Dermatology.
A new drug with the potential to join the existing class of monoclonal antibodies (mAbs) for plaque psoriasis has shown promising results in a Phase II study.
Ponesimod, a selective S1P1 receptor agonist, has been shown to be efficacious for improving both disease and quality of life markers in patients with moderate to severe chronic plaque psoriasis.
Otezla (apremilast) is an oral, selective phosphodiesterase 4 (PDE4) inhibitor for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
Ixekizumab, a drug being evaluated for the treatment of moderate-to-severe chronic plaque psoriasis, continues to demonstrate efficacy and safety in Phase III trials.
The National Psoriasis Foundation (NPF) recently announced a number of new programs and a five-year strategic mission for the organization with initiatives that are designed to increase research and uncover new treatments for all forms of psoriasis and psoriatic disease.